Its platform incorporates biology while selecting purified, full-length human IgGs. The company’s platform also delivers and optimizes diverse panels of therapeutically relevant antibodies that meet the most standards for affinity, epitope coverage, species cross-reactivity, and developability.

Adimab, LLC was founded in 2007 and is based in Lebanon, New Hampshire.